Answers are grounded in this paper and cite their sources.
Dr. Laghi proposes that all colorectal cancers be screened for microsatellite instability (MSI) using BAT26 as a marker rather than selecting patients based on family history for screening with the National Cancer Institute (NCI) panel of markers, as proposed in the revised Bethesda Guidelines (Table 1 ) ( 1 ) . This issue—that using just one MSI marker might make analysis simple and relatively inexpensive and hence would allow all patients with colorectal cancers to be screened, regardless of recommended screening guidelines—has been discussed before ( 2 ), and it needs careful examination, similar to what it received during the adoption of the NCI panel of markers. Most of the clinical and translational research experts did not feel that use of a single marker, even after applying screening guidelines, would identify the true number of hereditary nonpolyposis colorectal cancer (HNPCC) cases. In this Workshop, it was recognized that although markers like BAT26 are effective at determining MSI, they are not 100% sensitive (no false-negatives) or 100% specific (no false-positives), as suggested by Dr. Laghi. For example, BAT26 revealed MSI in 73 of 494 colorectal cancer patients, but when five markers were used, the number of patients with MSI increased to 95 of 494 ( 3 ) . Similarly, of 20 ovarian cancers with confirmed MSI, only five showed BAT26 instability ( 4 ), confirming results found in the literature for ovarian and endometrial cancers. Let us compare the cost-effectiveness of MSI screening using a single marker on all colorectal cancer patients versus screening based on family history and either the Amsterdam or the revised Bethesda Guidelines (Fig. 1 ). For instance, if all colorectal cancer cases [approximately 500 000 worldwide, and 147 000 in the United States ( 5 ) ] are to be analyzed for MSI at approximately $300 per primer pair for MSI analysis using one marker ( 6 ), the cost will be approximately $13 million per year in the United States and $150 million per year worldwide. However, using a screening guideline to reduce the number of MSI analyses performed can reduce the cost by as much as one-third (or approximately $3 million in the United States) and one-fourth (approximately $50 million worldwide), according to rough estimates based on suspected HNPCC/MSI cases (Ramsey S: personal communication). The issue of cost-effectiveness of any marker panel boils down to the relative cost and sensitivity and specificity of each approach. Alternative markers must be at least as sensitive (at equal specificity) and cost less than screening with the NCI panel of markers to improve the cost-effectiveness of screening probands. This explains why it would not be a good idea to perform MSI analysis on all colorectal cancer patients and emphasizes the importance of using family history and a well thought-out set of guidelines [Amsterdam, Bethesda, or one of the newly developed Asian guidelines ( 7 ) ] to ensure that the maximum number of individuals at risk of developing MSI colorectal cancer are screened. Decision algorithms for using either BAT26 alone or in combination with screening guidelines, such as the revised Bethesda Guidelines, to determine the number of individuals that will undergo genetic testing. The Revised Bethesda Guidelines for testing colorectal tumors for microsatellite instability (MSI) [adapted from ( 1 ) ] Colorectal cancer diagnosed in a patient who is less than 50 years of age. Presence of synchronous, metachronous colorectal, or other HNPCC-associated tumors, * regardless of age. Colorectal cancer with the MSI-H † histology ‡ diagnosed in a patient who is less than 60 years of age. § Colorectal cancer or HNPCC-associated tumor * diagnosed under age 50 years in at least one first-degree relative. ‖ Colorectal cancer or HNPCC-associated tumor * diagnosed at any age in two first- or second-degree relatives. ‖ Colorectal cancer diagnosed in a patient who is less than 50 years of age. Presence of synchronous, metachronous colorectal, or other HNPCC-associated tumors, * regardless of age. Colorectal cancer with the MSI-H † histology ‡ diagnosed in a patient who is less than 60 years of age. § Colorectal cancer or HNPCC-associated tumor * diagnosed under age 50 years in at least one first-degree relative. ‖ Colorectal cancer or HNPCC-associated tumor * diagnosed at any age in two first- or second-degree relatives. ‖ Hereditary nonpolyposis colorectal cancer (HNPCC)-associated tumors include colorectal, endometrial, stomach, ovarian, pancreas, ureter and renal pelvis, biliary tract, and brain (usually glioblastoma as seen in Turcot syndrome) tumors, sebaceous gland adenomas and keratoacanthomas in Muir-Torre syndrome, and carcinoma of the small bowel. MSI-H = microsatellite instability-high in tumors refers to changes in two or more of the five National Cancer Institute-recommended panels of microsatellite markers. Presence of tumor infiltrating lymphocytes. Crohn disease-like lymphocytic reaction, mucinous/ signet-ring differentiation, or medullary growth pattern. There was no consensus among the Workshop participants on whether to include the age criteria in guideline 3 above; participants voted to keep less than 60 years of age in the guidelines. Criteria 4 and 5 have been reworded to clarify the Revised Bethesda Guidelines. The Revised Bethesda Guidelines for testing colorectal tumors for microsatellite instability (MSI) [adapted from ( 1 ) ] Colorectal cancer diagnosed in a patient who is less than 50 years of age. Presence of synchronous, metachronous colorectal, or other HNPCC-associated tumors, * regardless of age. Colorectal cancer with the MSI-H † histology ‡ diagnosed in a patient who is less than 60 years of age. § Colorectal cancer or HNPCC-associated tumor * diagnosed under age 50 years in at least one first-degree relative. ‖ Colorectal cancer or HNPCC-associated tumor * diagnosed at any age in two first- or second-degree relatives. ‖ Colorectal cancer diagnosed in a patient who is less than 50 years of age. Presence of synchronous, metachronous colorectal, or other HNPCC-associated tumors, * regardless of age. Colorectal cancer with the MSI-H † histology ‡ diagnosed in a patient who is less than 60 years of age. § Colorectal cancer or HNPCC-associated tumor * diagnosed under age 50 years in at least one first-degree relative. ‖ Colorectal cancer or HNPCC-associated tumor * diagnosed at any age in two first- or second-degree relatives. ‖ Hereditary nonpolyposis colorectal cancer (HNPCC)-associated tumors include colorectal, endometrial, stomach, ovarian, pancreas, ureter and renal pelvis, biliary tract, and brain (usually glioblastoma as seen in Turcot syndrome) tumors, sebaceous gland adenomas and keratoacanthomas in Muir-Torre syndrome, and carcinoma of the small bowel. MSI-H = microsatellite instability-high in tumors refers to changes in two or more of the five National Cancer Institute-recommended panels of microsatellite markers. Presence of tumor infiltrating lymphocytes. Crohn disease-like lymphocytic reaction, mucinous/ signet-ring differentiation, or medullary growth pattern. There was no consensus among the Workshop participants on whether to include the age criteria in guideline 3 above; participants voted to keep less than 60 years of age in the guidelines. Criteria 4 and 5 have been reworded to clarify the Revised Bethesda Guidelines.
No takes yet. Share an insight, caveat, or question.
Asad Umar (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: